Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/40979
Type
ArticleCopyright
Restricted access
Embargo date
122020-01-01
Collections
Metadata
Show full item record
CLINICAL PRESENTATION AND RESPONSE TO THERAPY IN CHILDREN WITH CUTANEOUS LEISHMANIASIS
Author
Affilliation
Universidade Federal da Bahia. Faculdade de Medicina. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil.
Universidade Federal da Bahia. Faculdade de Medicina. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil.
University of Massachusetts Boston. Boston, Massachusetts.
Universidade Federal da Bahia. Faculdade de Medicina. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil.
Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil / Universidade Federal do Sul da Bahia. Ilhéus, BA, Brasil.
The University of Sheffield. Sheffield, England.
Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil / Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil.
Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil.
Universidade Federal da Bahia. Faculdade de Medicina. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil.
University of Massachusetts Boston. Boston, Massachusetts.
Universidade Federal da Bahia. Faculdade de Medicina. Pós-Graduação em Ciências da Saúde. Salvador, BA, Brasil / Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil / Universidade Federal da Bahia. Instituto de Ciências da Saúde. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil.
Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil / Universidade Federal do Sul da Bahia. Ilhéus, BA, Brasil.
The University of Sheffield. Sheffield, England.
Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil / Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil.
Universidade Federal da Bahia. Serviço de Imunologia do Complexo Hospitalar Universitário Professor Edgard Santos. Salvador, BA, Brasil / Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Salvador, BA, Brasil / Ministry of Science and Technology. National Institutes of Science and Technology in Tropical Diseases. Salvador, BA, Brazil.
Abstract
Cutaneous leishmaniasis (CL) caused by Leishmania braziliensis occurs predominantly in adult males. Herein, we compare the clinical presentation and the response to antimony therapy of CL in children versus adults. Participants included 571 patients with CL; of these, 129 were children (age ≤ 12 years). Cure was defined as the complete healing of ulcer in the absence of raised borders at day 90 after initiation of therapy. Failure was defined by the presence of an active ulcer or a scar with elevated borders at day 90. In comparison with adults, children had shorter duration of illness, more lesions in the head, and smaller ulcers. Risk factors for therapeutic failure were younger age, shorter duration of disease, higher number of lesions, and larger size of the biggest ulcer. When age was categorized in ≤ 12-year-olds (children versus adults), it predicted therapeutic failure with statistical significance at day 60 but not at day 90. In conclusion, our data indicate that there are significant differences in the clinical presentation of CL between children and adults. Physicians caring for children with CL should be aware that lesions may take longer to heal and remain alert for the possibility of higher odds of therapeutic failure in this group.
Share